Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.80 |
| ▸ | CCR1 | P32246 | 1/20 | 0.65 |
| ▸ | CCR5 | P51681 | 1/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605161 | 0.85 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12849253 | 0.85 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL195030 | 0.80 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL196068 | 0.80 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12233199 | 0.80 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL13612603 | 0.79 | CCR2 (0.70) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL16104180 | 0.78 | CCR2 (0.81) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL3954242 | 0.77 | CCR2 (0.69) | CCR2RAB9A | |
| SCHEMBL8317734 | 0.77 | CCR2 (0.69) | CCR2RAB9A | |
| SCHEMBL4704983 | 0.75 | CCR2 (0.67) | CCR2CCR1CCR5CXCR4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | CCR2 1658/4885CCR1 1458/4885CCR5 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.